Onyx Bio has filed a notice of an exempt offering of securities to raise $7,999,999.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Onyx Bio is raising up to $7,999,999.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Onyx Bio
Onyx is building a virtual immune system for faster and safer development of precision medicines. Our research generates rich, longitudinal multiomics data anchored in clinical context, enabling us to deeply profile the progression of autoimmune diseases. At our core, we believe that high-quality biological data is the cornerstone of scientific advancement. As our biorespository and datasets grow, we apply advanced AI to gain unprecedented insight into immune function illuminating new frontiers in treatment and prevention. Join us in unraveling the intricacies of biology and ushering life sciences into the AI era. Together, we will tackle immune-related diseases that once seemed intractable and improve the lives of millions worldwide.
To learn more about Onyx Bio, visit https://www.onyx.bio/
Onyx Bio Linkedin Page: https://www.linkedin.com/company/onyxbio/
Contact:
Roger Chen, Chief Executive Officer
415-617-5959
https://www.linkedin.com/in/rgrchen/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
